메뉴 건너뛰기
Medical Science Monitor
Volumn 14, Issue 4, 2008, Pages
Rosiglitazone in the prevention of diabetes and cardiovascular disease: Dream or reality?
Author keywords

Adverse effects; Diabetes; Prevention; Rosiglitazone
Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;
EID: 42049090618     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (3)
References (4)
  • 1
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
    • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
    • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006; 368: 1096-105
    • (2006) Lancet , vol.368 , pp. 1096-1105
  • 2
    • 15944395414 scopus 로고    scopus 로고
    • Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program
    • Knowler WC, Hamman RF, Edelstein SL et al: Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes, 2005; 54: 1150-56
    • (2005) Diabetes , vol.54 , pp. 1150-1156
    • Knowler, W.C.1    Hamman, R.F.2    Edelstein, S.L.3
  • 3
    • 34250212715 scopus 로고    scopus 로고
    • Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
    • Nissen SE, Wolski K: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med, 2007; 356: 2457-71
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 4
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial
    • Dormandy JA, Charbonnel B, Eckland DJ et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005; 366: 1279-89
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.